Top Industry Leaders in the UTI treatment Market
Latest UTI treatment Companies Update
Spero Therapeutics receives FDA approval for Tepezza (tebipenem HBr tablets): October 2023, Spero Therapeutics secured FDA approval for Tepezza, the first oral antibiotic specifically developed for the treatment of complicated urinary tract infections (cUTIs). This marks a significant breakthrough in addressing antibiotic resistance concerns.
AstraZeneca acquires Neobιοtics: August 2023, AstraZeneca acquired Neobιοtics, a developer of microbiome-based therapeutics, aiming to leverage Neobιοtics' expertise in urinary tract health for the development of novel non-antibiotic UTI treatments.
BD launches BD Vacutainer® Rapid ID Urine UTI Test System: June 2023, BD introduced its BD Vacutainer® Rapid ID Urine UTI Test System, a point-of-care diagnostic tool that rapidly identifies common urinary tract pathogens and antibiotic susceptibility, enabling faster and more informed treatment decisions.
List of UTI treatment Key Companies in the Market
- Pfizer
- Cipla Inc.
- GlaxoSmithKline PLC
- Shionogi & Co. Ltd
- Novartis AG
- AstraZeneca
- Bayer AG